Edgewise Therapeutics Inc

NASDAQ:EWTX  
14.64
+0.10 (+0.69%)
Products, Regulatory

Edgewise Therapeutics Announces Positive Topline Results From The EDG-5506 Phase 1B Clinical Trial In Adults With Becker Muscular Dystrophy (BMD)

Published: 01/05/2022 19:06 GMT
Edgewise Therapeutics Inc (EWTX) - Edgewise Therapeutics Announces Positive Topline Results From the Edg-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (bmd).
Edgewise Therapeutics - Edg-5506 Was Well Tolerated With No Serious Adverse Events Observed.
Edgewise Therapeutics - Edg-5506 Treatment Resulted in Significant Lowering of Muscle Damage Biomarkers in Adults With Bmd After 2 Weeks of Dosing.